RxDoctor Payments Data

Disha Trivedi, MD

Nephrology · Melbourne, FLNPI 1750522264

Payments from drug & device makers

$1,600in general payments, 2019–2025

Across 77 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$703
  • Otsuka America Pharmaceutical, Inc.$237
  • Mallinckrodt Hospital Products Inc.$91
  • Calliditas Therapeutics US Inc.$85
  • Bayer$79
  • Fresenius USA Marketing, Inc.$72
  • plus $334 from 10 others

What the payments were for

  • Food & beverage$1,48393%
  • Education$1177%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,600 in reported general payments places this provider in the 45th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$390,843
Medicare patients
965
Services billed
3,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide28$78,882
FarxigaDapagliflozin Propanediol92$74,331
JardianceEmpagliflozin25$39,717
Sevelamer Hcl17$18,683
Sevelamer Carbonate29$7,687
LokelmaSodium Zirconium Cyclosilicate11$6,568
Calcium Acetate42$4,369
Bumetanide73$2,702
Hydralazine Hcl140$1,885
Nifedipine ErNifedipine52$1,810
Labetalol Hcl58$1,712
Calcitriol123$1,233
Allopurinol118$1,192
Potassium Citrate ErPotassium Citrate15$1,056
Losartan Potassium88$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$703$80,898103 claims
Fresenius USA Marketing, Inc.Velphoro$72$78,88228 claims
Boehringer IngelheimJardiance$29$39,71725 claims
ANI Pharmaceuticals, Inc.Valsartan$36$97217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 756 nephrology providers in Florida.

Other nephrology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →